These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 34905526)

  • 1. The Effect of Intravitreal Ocriplasmin on Hue Discrimination.
    Neffendorf JE; Kirthi V; Soare C; Jackson TL
    Optom Vis Sci; 2021 Dec; 98(12):1394-1399. PubMed ID: 34905526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral vitreomacular traction resolved with a single intravitreal ocriplasmin injection.
    Katz RS
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(3):239-42. PubMed ID: 24708167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.
    Mein C; Dugel PU; Feiner L; Drenser K; Miller D; Benz M; Meunier E; Moro L; Fineman MS
    Retina; 2020 Jul; 40(7):1331-1338. PubMed ID: 31259807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocriplasmin for symptomatic vitreomacular adhesion.
    Neffendorf JE; Kirthi V; Pringle E; Jackson TL
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
    Dugel PU; Regillo C; Eliott D
    Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
    Jackson TL; Regillo CD; Girach A; Dugel PU;
    Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
    Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
    Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of ocriplasmin versus watchful waiting for treatment of symptomatic vitreomacular adhesion in the US.
    Khanani AM; Dugel PU; Haller JA; Wagner AL; Lescrauwaet B; Schmidt R; Bennison C
    J Comp Eff Res; 2020 Mar; 9(4):287-305. PubMed ID: 31961196
    [No Abstract]   [Full Text] [Related]  

  • 18. Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion.
    Meyer JC; Shah GK; Blinder KJ; Waheed NK; Reichel E; Stalmans P; Singer M; Tewari A
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):209-16. PubMed ID: 25707046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.
    Sadda SR; Dugel PU; Gonzalez VH; Meunier E; Kozma P
    Retina; 2019 Feb; 39(2):319-330. PubMed ID: 29206755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term changes in posterior vitreous cortex following intravitreal ocriplasmin for symptomatic vitreomacular traction syndrome: a prospective study.
    Cacciamani A; Gattegna R; Pileri M; Di Nicola M; Bardanzellu S; Facciolo G; Cosimi P; Govetto A; Scarinci F
    Int Ophthalmol; 2020 Jan; 40(1):185-193. PubMed ID: 31565760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.